Puma Biotechnology, Inc. (PBYI)
- Previous Close
4.8300 - Open
5.0900 - Bid 4.8600 x 100
- Ask 4.8900 x 100
- Day's Range
4.7200 - 5.0600 - 52 Week Range
2.1300 - 7.7300 - Volume
229,936 - Avg. Volume
584,414 - Market Cap (intraday)
235.251M - Beta (5Y Monthly) 1.31
- PE Ratio (TTM)
10.84 - EPS (TTM)
0.4500 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.33
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
www.pumabiotechnology.comRecent News: PBYI
Performance Overview: PBYI
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PBYI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PBYI
Valuation Measures
Market Cap
232.84M
Enterprise Value
248.39M
Trailing P/E
10.73
Forward P/E
9.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.97
Price/Book (mrq)
4.36
Enterprise Value/Revenue
1.05
Enterprise Value/EBITDA
5.23
Financial Highlights
Profitability and Income Statement
Profit Margin
9.16%
Return on Assets (ttm)
9.19%
Return on Equity (ttm)
57.54%
Revenue (ttm)
235.64M
Net Income Avi to Common (ttm)
21.59M
Diluted EPS (ttm)
0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
95.94M
Total Debt/Equity (mrq)
208.62%
Levered Free Cash Flow (ttm)
1.79M